Literature DB >> 24364263

Application of splenectomy to decompress portal pressure in left lobe living donor liver transplantation.

Toru Ikegami1, Tomoharu Yoshizumi2, Yuji Soejima2, Tetsuo Ikeda2, Hirofumi Kawanaka2, Hideaki Uchiyama2, Yo-ichi Yamashita2, Masaru Morita2, Eiji Oki2, Hiroshi Saeki2, Koshi Mimori3, Keishi Sugimachi2, Masayuki Watanabe4, Ken Shirabe2, Yoshihiko Maehara2.   

Abstract

This study was conducted to evaluate the impact of splenectomy in living donor liver transplantation (LDLT) using left lobe grafts. The two hundred and fifty LDLT cases were divided into two groups: Group-S (n = 98, simultaneous splenectomy) and Group-NS (n = 152). Group-S had significantly increased recipient age (54.5 +/- 10.9 years vs. 46.3 +/- 17.0 years, p < 0.01), advanced liver diseases including Child class C (64.8% vs. 51.5%, p < 0.01), higher model for end-stage liver score (17.8 +/- 8.1 vs. 15.4 +/- 5.8, p < 0.01) and more patients with hospitalized status (67.4% vs. 48.0%, p < 0.01), and smaller graft volume/standard liver volume ratio (36.5 +/- 6.1% vs. 40.2 +/- 8.2%, p < 0.01). In Group-S, splenectomy decreased portal venous (PV) pressure decreased from 23.5 +/- 5.2 mmHg to 19.2 +/- 4.8 mmHg (p < 0.01). Group-S had significantly increased PV pressure at laparotomy (24.9 +/- 5.3 mmHg vs. 22.5 +/- 6.3 mmHg, p < 0.01) and decreased PV pressure at closure (16.4 +/- 3.5 mmHg vs. 18.0 +/- 4.7 mmHg, p < 0.01), compared with Group-NS. On the 14th day after LDLT, Group-S had lower total bilirubin (5.7 +/- 6.5 mg/dl vs. 8.7 +/- 8.9 mg/dl, p < 0.01) and smaller ascites output (0.4 +/- 0.7 L/day vs. 0.7 +/- 0.4 L/day, p = 0.01) than Group-NS. The cumulative 5-year graft survival rate was 86.8% in Group-S and 76.2% in Group-NS (p = 0.03). In conclusion, splenectomy had beneficial impacts on graft outcomes in left-lobe LDLT.

Entities:  

Mesh:

Year:  2013        PMID: 24364263

Source DB:  PubMed          Journal:  Fukuoka Igaku Zasshi        ISSN: 0016-254X


  3 in total

1.  Modulation of hepatic perfusion did not improve recovery from hepatic outflow obstruction.

Authors:  J Arlt; W Wei; C Xie; A Homeyer; U Settmacher; U Dahmen; O Dirsch
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-26       Impact factor: 2.483

2.  Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports.

Authors:  Guoyong Chen; Janjun Sun; Sidong Wei; Yongfeng Chen; Gaofeng Tang; Zhantao Xie; Huaen Xu; Janbin Chen; Huibo Zhao; Zhenhua Yuan; Weiwei Wang; Guangbo Liu; Bing Wang; Biao Niu
Journal:  J Int Med Res       Date:  2017-06-21       Impact factor: 1.671

3.  Selective gene expression profiling contributes to a better understanding of the molecular pathways underlying the histological changes observed after RHMVL.

Authors:  Janine Arlt; Sebastian Vlaic; Ronny Feuer; Maria Thomas; Utz Settmacher; Uta Dahmen; Olaf Dirsch
Journal:  BMC Med Genomics       Date:  2022-10-07       Impact factor: 3.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.